Brookstone Capital Management’s Biogen BIIB Stock Holding History

Brookstone Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-14,994	Closed	-$4.12M	–	833
2023 Q2	$4.12M	Buy	14,994 +3,411	+29%	+$1.02M	0.08%	221
2023 Q1	$3.38M	Buy	11,583 +2,944	+34%	+$815K	0.07%	244
2022 Q4	$2.41M	Buy	8,639 +1,404	+19%	+$397K	0.05%	280
2022 Q3	$1.83M	Buy	7,235 +2,242	+45%	+$476K	0.04%	300
2022 Q2	$1.09M	Buy	4,993 +926	+23%	+$189K	0.02%	387
2022 Q1	$857K	Buy	4,067 +1,909	+88%	+$415K	0.02%	446
2021 Q4	$502K	Buy	2,158 +409	+23%	+$105K	0.01%	526
2021 Q3	$496K	Buy	1,749 +1,073	+159%	+$352K	0.01%	502
2021 Q2	$238K	Buy	+676	New	+$205K	﹤0.01%	641
2015 Q4	–	Sell	-25	Closed	-$7K	–	231
2015 Q3	$7K	Sell	25 -17	-40%	-$5.61K	﹤0.01%	1279
2015 Q2	$17K	Buy	+42	New	+$16.9K	﹤0.01%	936

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Brookstone Capital Management's BIIB Position: Q3 2023 in Review

Brookstone Capital Management sold out of Biogen (BIIB) in Q3 2023, closing a stake of 14,994 shares — an estimated $4.12M sold.

Brookstone Capital Management first reported a position in BIIB in Q2 2015 and held it in 11 quarters. The position peaked at $4.12M in Q2 2023. 965 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.

Brookstone Capital Management reported no remaining Biogen position as of Q3 2023 after selling out during the quarter.
Brookstone Capital Management sold 14,994 Biogen shares in Q3 2023, an estimated $4.12M.
Brookstone Capital Management first reported a position in Biogen in Q2 2015 and held it in 11 quarters.
Brookstone Capital Management's Biogen position peaked at $4.12M in Q2 2023.
965 funds tracked by Wall St. Rank held Biogen as of Q3 2023.

Based on Brookstone Capital Management's 13F filing for Q3 2023, filed 20 Oct 2023.